| 2.71 0.02 (0.74%) | 06-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.36 | 1-year : | 3.59 |
| Resists | First : | 2.88 | Second : | 3.07 |
| Pivot price | 2.71  |
|||
| Supports | First : | 2.55 | Second : | 2.12 |
| MAs | MA(5) : | 2.63  |
MA(20) : | 2.78 |
| MA(100) : | 2.95 |
MA(250) : | 3.35 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 26.8 |
D(3) : | 18 |
| RSI | RSI(14): 46.1 |
|||
| 52-week | High : | 4.42 | Low : | 2.3 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ EVO ] has closed above bottom band by 49.5%. Bollinger Bands are 39.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.76 - 2.77 | 2.77 - 2.79 |
| Low: | 2.64 - 2.65 | 2.65 - 2.67 |
| Close: | 2.69 - 2.71 | 2.71 - 2.73 |
Evotec SE operates globally as a dedicated partner, specializing in the discovery and advancement of new pharmaceutical products for the biotechnology and pharmaceutical sectors. Its comprehensive research and development initiatives encompass a broad spectrum of medical areas, such as metabolic disorders (including diabetes and its complications), fibrosis, infectious conditions, central nervous system (CNS) diseases, oncology, pain management, inflammatory ailments, immunological dysfunctions, rare diseases, respiratory conditions, and women's health. The company maintains strategic alliances and collaborations with numerous prominent organizations, including Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd, Kazia Therapeutics, Apeiron Biologics, and Takeda Pharmaceuticals. Established in 1993, the company was formerly known as Evotec AG, changing its name to Evotec SE in April 2019. Its corporate headquarters are located in Hamburg, Germany.
Thu, 25 Jun 2026
Evotec lowers FY25 revenue forecast, keeps profit targets & confirms long-term 2028 outlook - MSN
Thu, 18 Jun 2026
Evotec SE (EVO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Thu, 18 Jun 2026
Evotec (EVO) Short Interest & Short Float | Updated Jun 2026 $EVO - MarketBeat
Wed, 17 Jun 2026
Director share sale disclosed by Evotec (EVO) in June 2026 filing - Stock Titan
Tue, 12 May 2026
Evotec SE (EVO) Issues €116.1M Convertible Bonds to Support Proj - GuruFocus
Thu, 07 May 2026
Evotec SE Posts Weak Q1 2026 but Doubles Down on ‘Horizon’ Transformation and Mid-Term Growth Targets - The Globe and Mail
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 355 (M) |
| Shares Float | 267 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 2.1 (%) |
| Shares Short | 75 (K) |
| Shares Short P.Month | 86 (K) |
| EPS | -0.63 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.26 |
| Profit Margin | -26.1 % |
| Operating Margin | -29.7 % |
| Return on Assets (ttm) | -3.2 % |
| Return on Equity (ttm) | -24.1 % |
| Qtrly Rev. Growth | -21.8 % |
| Gross Profit (p.s.) | 0.22 |
| Sales Per Share | 2.09 |
| EBITDA (p.s.) | -0.05 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 19 (M) |
| Levered Free Cash Flow | 99 (M) |
| PE Ratio | -4.31 |
| PEG Ratio | 1.4 |
| Price to Book value | 1.19 |
| Price to Sales | 1.29 |
| Price to Cash Flow | 51.44 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|